Advenchen Lab’s AL8326 and Hengrui’s SHR-A1811 Receive Breakthrough Therapy Designations
The Center for Drug Evaluation (CDE) website indicates that Advenchen Lab’s AL8326 and Hengrui Pharmaceuticals’...
Merck & Peking University Launch Public Health Training Projects for Young and Middle-Aged Talent
Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) and the Peking University School of Public...
Biokin’s BL-B01D1 Receives NMPA Approval for Phase II Solid Tumor Study
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has received approval...
Junshi Biosciences’ JS010 Receives NMPA Approval for Migraine Clinical Trials
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that it has received clinical trial...
Immunotech Biopharm’s CAR-T-19-D2 Receives NMPA Approval for DLBCL Clinical Trial
China-based chimeric antigen receptor T-cell (CAR-T) specialist Immunotech Biopharm Ltd (HKG: 6978) has announced that...
Smith & Nephew Partners with MedMotion for Digital Health Innovation
UK-based Smith & Nephew Plc has announced a strategic partnership with China’s Shanghai Fudong Medical...
Aidea Pharma and China Meheco Partner to Expand Medical and Pharmaceutical Services
China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced a partnership with China Meheco...
3SBio Inc. Reports 7.5% Revenue Growth in 2022 Financials
China-based 3SBio Inc. (HKG: 1530) released its 2022 financial report, recording revenues of RMB 6.859...
Joincare Pharmaceutical Acquires Rights to TaiGen’s PA Endonuclease Inhibitor TG-1000
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced a licensing agreement with...
Reistone Biopharma’s Ivarmacitinib Shows Positive Results in Phase III QUARTZ3 Study
Reistone Biopharma Co., Ltd, incubated by Hengrui Pharmaceuticals (SHA: 600276) with USD 100 million in...
Sinopharm Forms Joint Ventures with Foreign Medical Equipment Firms
Sinopharm China National Biotech Group Co., Ltd (CNBG) has announced partnerships with two foreign medical...
BeiGene Marks Topping Off of New Biologics Facility in New Jersey
China-based biotech BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) held a ceremony to mark the...
Roche Partners with China Resource Medicine to Promote Xofluza in China
Swiss pharmaceutical giant Roche (SWX: ROG) has entered into a partnership with China-based China Resource...
Jacobio Pharma Partners with Merck to Evaluate CD73 mAb and Keytruda Combination
China-based Jacobio Pharma (HKG: 1167) has announced a clinical partnership with Merck, Sharp & Dohme...
Yifan Pharmaceutical’s F-652 Cleared for Phase II Trial in Alcoholic Hepatitis
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced that its subsidiary Evive Biotech Ltd’s...
BioNTech Acquires Global Rights to OncoC4’s Anti-CTLA-4 Antibody ONC-392
Germany-based mRNA specialist BioNTech SE (NASDAQ: BNTX) has unveiled a licensing deal and collaboration with...
Cygnus Bio Raises Millions in Series C+ Financing for Sequencing Technology
Beijing-based second-generation sequencing technology platform Cygnus Bio has reportedly raised “hundreds of millions” of renminbi...
L&L Biopharma Completes Series B Financing for Tumor Immunotherapy Development
Shanghai-based tumor immunotherapy developer L&L Biopharma Co., Ltd has announced the completion of a Series...
T&L Biotechnology Secures RMB 100 Million in Series A Financing
Beijing-based cell and gene therapy (CGT) developer T&L Biotechnology Co., Ltd has reportedly raised RMB...
Yiling Pharmaceutical’s BIO-008 Receives NMPA Approval for Clinical Trials
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that it has received clinical trial...